News stories about CASI Pharmaceuticals (NASDAQ:CASI) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. CASI Pharmaceuticals earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.0191057184853 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

Shares of CASI Pharmaceuticals (NASDAQ:CASI) traded down $0.11 during mid-day trading on Monday, hitting $3.89. 215,800 shares of the stock were exchanged, compared to its average volume of 257,070. CASI Pharmaceuticals has a 52 week low of $0.91 and a 52 week high of $4.84. The firm has a market cap of $271.93, a PE ratio of -25.93 and a beta of 0.71.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.01. equities research analysts expect that CASI Pharmaceuticals will post -0.13 earnings per share for the current fiscal year.

A number of brokerages have recently issued reports on CASI. HC Wainwright restated a “buy” rating and issued a $4.50 price objective on shares of CASI Pharmaceuticals in a research note on Monday, January 29th. Maxim Group set a $4.00 price objective on shares of CASI Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 14th.

TRADEMARK VIOLATION NOTICE: This news story was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was stolen and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this news story can be read at https://theolympiareport.com/2018/02/12/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-casi-pharmaceuticals-casi-stock-price.html.

CASI Pharmaceuticals Company Profile

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Insider Buying and Selling by Quarter for CASI Pharmaceuticals (NASDAQ:CASI)

Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.